Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYHA1813 + cisplatin
- Development stage
- Phase 2
- Lead developer
- Shanghai Runshi Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SYHA1813 + cisplatin is an experimental combination therapy comprised of SYHA1813, a potent, orally bioavailable small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) and colony-stimulating factor 1 receptor (CSF1R), and cisplatin, a platinum-based chemotherapeutic agent. SYHA1813 exhibits anti-angiogenic and immunomodulatory effects by blocking VEGFR-dependent neovascularization and CSF1R-driven macrophage-mediated mechanisms. Cisplatin intercalates DNA to induce apoptosis. The combination is under investigation for synergistic antitumor activity, particularly in high-grade gliomas and selected solid tumors.
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNA
Beyond the preview
Go deeper on SYHA1813 + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYHA1813 + cisplatin.